Budget impact of adding lesinurad for second-line treatment of gout: a US health plan perspective.

08:00 EDT 24th May 2018 | BioPortfolio

Summary of "Budget impact of adding lesinurad for second-line treatment of gout: a US health plan perspective."

Estimate budget impact of adopting lesinurad as add-on to allopurinol for urate-lowering therapy in gout.


Journal Details

This article was published in the following journal.

Name: Journal of comparative effectiveness research
ISSN: 2042-6313


DeepDyve research library

PubMed Articles [26528 Associated PubMed Articles listed on BioPortfolio]

International position paper on the appropriate use of uricosurics with the introduction of lesinurad.

Over the last 70 years, pharmacotherapy in gout with urate-lowering drugs has consisted of four drugs only: In 1952, a mild uricosuric probenecid became available, the xanthine oxidase inhibitor Allo...

Acute Gout in Emergency Admissions - Patient Characteristics and Adherence of Care Processes to Current Guidelines.

Gout or hyperuricemia are both well known and common diseases. The prevalence of gout is increasing worldwide. Thus, patients with gout are becoming more common. Although there are several published g...

Urate and Osteoarthritis: Evidence For a Reciprocal Relationship.

Hyperuricemia is a common condition, and in a subset of patients leads to gout, the most common inflammatory arthritis. Osteoarthritis is the most common form of arthritis overall, and gout and osteoa...

Budget impact analysis of long-acting injectable aripiprazole once-monthly 400 mg in bipolar I disorder in the USA.

To estimate the budget impact (BI) of introducing aripiprazole once-monthly 400 mg/300 mg (AOM 400) in the maintenance monotherapy treatment of bipolar I disorder versus long-acting injectables, oral ...

Multiwavelength UV-metric and pH-metric determination of the multiple dissociation constants of the lesinurad.

Potentiometric and spectrophotometric pH-titrations of the lesinurad for three consecutive dissociation constants determination were compared. Lesinurad is a selective inhibitor of uric acid reabsorpt...

Clinical Trials [6390 Associated Clinical Trials listed on BioPortfolio]

Lesinurad/Allopurinol 200/300 FDC Tablets Bioequivalence.

To assess the bioequivalence between lesinurad/allopurinol 200/300 FDC tablets and coadministered lesinurad and allopurinol tablets in the fasted state based on the pharmacokinetic evaluat...

Bioavailability of Lesinurad and Intravenous [14C]Lesinurad

This study will assess the absolute bioavailability of a single oral dose of lesinurad and evaluate the pharmacokinetic (PK) parameters of lesinurad and [14C]lesinurad in healthy adult mal...

Lesinurad/Allopurinol 200/300 FDC Tablets Bioequivalence

This study will assess the bioequivalence (BE) of Lesinurad/Allopurinol Fixed-Dose Combination (FDC) Tablets and Coadministered Lesinurad and Allopurinol Tablets in Fed Healthy Adult Subje...

Pegylated Recombinant Mammalian Uricase (PEG-uricase) as Treatment for Refractory Gout

The purpose of this study is to determine whether PEG-uricase (a chemically modified recombinant mammalian enzyme that degrades uric acid) is effective in controlling hyperuricemia in pati...

Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use NSAIDs and/or Colchicines.

The purpose of this study is to demonstrate that canakinumab given upon acute gout flares relieves the signs and symptoms and prevents recurrence of gout flares in patients with frequent f...

Medical and Biotech [MESH] Definitions

Uricosuric that acts by increasing uric acid clearance. It is used in the treatment of gout.

An anti-inflammatory agent used in the treatment of rheumatoid arthritis. It also has uricosuric properties and has been used to treat gout.

A thiazole derivative and inhibitor of XANTHINE OXIDASE that is used for the treatment of HYPERURICEMIA in patients with chronic GOUT.

The Commission was created by the Balanced Budget Act of 1997 under Title XVIII. It is specifically charged to review the effect of Medicare+Choice under Medicare Part C and to review payment policies under Parts A and B. It is also generally charged to evaluate the effect of prospective payment policies and their impact on health care delivery in the US. The former Prospective Payment Assessment Commission (ProPAC) and the Physician Payment Review Commission (PPRC) were merged to form MEDPAC.

Agents that increase uric acid excretion by the kidney (URICOSURIC AGENTS), decrease uric acid production (antihyperuricemics), or alleviate the pain and inflammation of acute attacks of gout.

Quick Search


DeepDyve research library

Relevant Topics

According to the National Arthritis Data Workgroup, an estimated 6 million people in the United States report having experienced gout at some point in their lives. In fact, gout is the most common form of inflammatory arthritis in men over the age of 40....

Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...

Searches Linking to this Article